Results 1 to 10 of about 4,717,412 (218)

DDIAS promotes endometrial cancer progression via β-catenin signaling. [PDF]

PLoS ONE
BackgroundDDIAS has been recognized as an oncogene in various cancers, but its role in endometrial cancer remains unexplored.MethodsThe expression of DDIAS in normal endometrium and endometrial cancer samples was analysed via the The Cancer Genome Atlas (
Xiaojuan Tian, Menglu Liu, Jiangbo Zhao, Chusi Lao, Boya Liu, Yuping Suo   +5 more
doaj   +2 more sources

Expert consensus on genetic counseling in gynecological oncology (2023 edition) [PDF]

Zhongguo aizheng zazhi, 2023
With the increasing applications of high-throughput genome sequencing technology, there is a growing recognition of the important roles of genetic factors in the occurrence and development of gynecological tumors.

doaj   +1 more source

FIGO staging of endometrial cancer: 2023

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023
Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009.
Jonathan S Berek, X. Matías-Guiu, C. Creutzberg, C. Fotopoulou, D. Gaffney, S. Kehoe, K. Lindemann, D. Mutch, N. Concin   +8 more
semanticscholar   +2 more sources

Expression of STAT3 in endometrial carcinoma and its clinicopathological significance [PDF]

Jichu yixue yu linchuang, 2023
Objective To investigate the expression of signal transducer and activator of transcription 3 (STAT3) in endometrial cancer tissues, and to analyze its relationship with common pathological parameters.
SUN Xinzhao, LUO Yanlu, FAN Jiangtao, ZHONG Xueyan
doaj   +1 more source

Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention

Biomolecules & Biomedicine, 2022
Endometrial cancer is the second gynecological cancer with the highest global incidence. Among many associated risk factors, metabolic syndrome is an important and preventable one.
Alejandra Rocío Pérez-Martín, Denisse Castro-Eguiluz , Lucely Cetina-Pérez, Yadira Velasco-Torres, Antonio Bahena-González, Edgar Montes-Servín, Ernesto González-Ibarra, Raquel Espinosa-Romero, Dolores Gallardo-Rincón   +8 more
doaj   +1 more source

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer.
M. Mirza, D. Chase, B. Slomovitz, René dePont Christensen, Z. Novak, D. Black, L. Gilbert, Sudarshan Sharma, G. Valabrega, L. Landrum, L. Hanker, A. Stuckey, I. Boere, M. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M. Shahin, S. Gill, B. Monk, J. Buscema, T. Herzog, L. Copeland, Min Tian, Zangdong He, S. Stevens, E. Zografos, R. Coleman, M. Powell   +30 more
semanticscholar   +1 more source

Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12

Frontiers in Genetics, 2022
Background: Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13–17% of ovarian cancers are due to heritable mutations in BRCA1 and BRCA2.
Dolores Gallardo-Rincón, Dolores Gallardo-Rincón, Edgar Montes-Servín, Gabriela Alamilla-García, Gabriela Alamilla-García, Elizabeth Montes-Servín, Antonio Bahena-González, Antonio Bahena-González, Lucely Cetina-Pérez, Lucely Cetina-Pérez, Flavia Morales Vásquez, Claudia Cano-Blanco, Jaime Coronel-Martínez, Ernesto González-Ibarra, Raquel Espinosa-Romero, Raquel Espinosa-Romero, Rosa María Alvarez-Gómez, Rosa María Alvarez-Gómez, Abraham Pedroza-Torres, Abraham Pedroza-Torres, Denisse Castro-Eguiluz, Denisse Castro-Eguiluz   +21 more
doaj   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander, M. Sill, L. Beffa, Richard G. Moore, J. Hope, Fernanda B. Musa, R. Mannel, M. Shahin, G. Cantuaria, E. Girda, C. Mathews, J. Kavecansky, Charles A Leath Iii, L. Gien, E. Hinchcliff, S. Lele, L. Landrum, F. Backes, R. O'Cearbhaill, T. Al baghdadi, E. Hill, P. Thaker, V. John, S. Welch, A. Fader, M. Powell, C. Aghajanian   +26 more
semanticscholar   +1 more source

Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study

Frontiers in Oncology, 2021
BackgroundAlthough the guidelines recommend gynecological assessment and close monitoring for symptoms of endometrial cancer in postmenopausal breast cancer survivors taking tamoxifen (TAM), the risk of endometrial cancer in young breast cancer survivors
Soojeong Choi, Young Jae Lee, Jae Ho Jeong, Jinhong Jung, Jong Won Lee, Hee Jeong Kim, Beom Seok Ko, Byung Ho Son, Sei Hyun Ahn, Yura Lee, Yura Lee, Il Yong Chung   +11 more
doaj   +1 more source

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

New England Journal of Medicine, 2022
BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously ...
V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. Guerra, U. Şanlı, M. McCormack, Alan Smith, S. Keefe, Steven Bird, L. Dutta, R. Orlowski, D. Lorusso   +23 more
semanticscholar   +1 more source